In the present work, we show that mithramycin A, a drug that is currently used for the treatment of patients with Paget's disease of the bone as well as with several forms of cancer, is a strong activator of the tumor suppressor p53 protein in human hepatoma cells. The time course of p53 activation by mithramycin A was similar to the known chemotherapeutic compound 5-fluorouracil (5-FU). Both 5-FU and mithramycin A induced site-specific phosphorylation of p53 at serine 15. However, in contrast to 5-FU, mithramycin A failed to activate p53 target genes including the cell cycle inhibitor p21
Introduction
The p53 protein plays a central role in a protein network that controls cell cycle progression, differentiation, DNA repair and apoptosis (Levine, 1997; Vogelstein et al., 2000) . p53 acts as a tumor suppressor as documented by the finding that mice in which the p53 gene was inactivated by homologous recombination developed spontaneously tumors at a young age (Choi and Donehower, 1999) .
Agents that cause DNA damage such as UV radiation, hypoxia or certain carcinogens activate p53 by inducing its phosphorylation at specific serine residues (Kohn, 1999) . The activation of p53 by the above agents induces either cell cycle arrest or apoptotic cell death depending on the cellular context and condition (Vogelstein et al., 2000) . Recently, the gene encoding the cytochromic PUMA (p53-upregulated mediator of apotosis) protein was shown to be a key mediator of the apoptotic response of cells to p53 induction (Yu et al., 2001; . On the other hand, strong experimental evidence suggests that the cell cycle arrest effect of p53 is mediated by the transcriptional activation of the cell cycle inhibitor p21 Cip1 (Levine, 1997; Vogelstein et al., 2000) . p21
Cip1 is a ubiquitously expressed protein that is involved in the regulation of cell cycle progression in mammalian cells (Harper and Elledge, 1996; Dotto, 2000) . p21
Cip1 is found in complexes consisting of cyclins, cyclin-dependent kinases (cdks) and Proliferating Cell Nuclear Antigen, a subunit of DNA polymerase d (Zhang et al., 1993) . The formation of these complexes is essential for cell cycle progression (Zhang et al., 1994; Cheng et al., 1999) . However, changes in p21 Cip1 stoichiometry result in suppression of cdk activity, accumulation of hypophosphorylated retinoblastoma (Rb) protein and cell cycle arrest in G1 (Harper et al., 1995; Harper and Elledge, 1996) . Overexpression of p21
Cip1 has been shown to inhibit p53-dependent and independent apoptosis (Gartel and Tyner, 2002) . In contrast, inactivation of the p21
Cip1 gene by homologous recombination or inhibition of its expression by the c-myc oncogene enhances apoptosis in response to genotoxic agents, suggesting that p21
Cip1 plays a protective role in apoptosis (Seoane et al., 2002; Yu et al., 2003) .
In the present study, we investigated the effect of two chemotherapeutic compounds with different mechanisms of cytotoxicity (mithramycin A and 5-fluorouracil (5-FU)) on the expression of the p53 and its target genes in human hepatoma HepG2 cells. Mithramycin A (also known as aureolic acid, mithracin or plicamycin) is an aureolic acid-type polyketide produced by the soil bacteria Streptomyces argillaceus (Jayasuriya et al., 2002) . Mithramycin A inhibits bone resorption by preventing the synthesis of the c-src oncogene in the osteoclast and has been used clinically in the US to treat Paget's disease of the bone and testicular carcinoma (Brown and Kennedy, 1965; Ryan et al, 1970; Elias and Evans, 1972; Hall et al., 1993; Remsing et al., 2003) . Mithramycin A is a drug that binds to GC-rich regions in chromatin and interferes with the transcription of genes that bear GC-rich motifs in their promoters (Miller et al., 1987; Ray et al., 1989; Blume et al., 1991; Snyder et al., 1991; Nehls et al., 1993; Aich and Dasgupta, 1995; . 5-FU acts as a DNA-damaging agent by its ability to be misincorporated into DNA and RNA during replication and transcription, respectively, and to inhibit the enzyme thymidylate synthase (Longley et al., 2003) . 5-FU is frequently used in the treatment of a wide range of cancers, including colorectal and breast cancers, and cancers of the aerodigestive tract (Longley et al., 2003) . We found that both mithramycin A and 5-FU strongly activated p53 by inducing its phosphorylation specifically at serine 15. However, in contrast to 5-FU, mithramycin A failed to activate the expression of the p53-target genes p21
Cip1
, PUMA and BAK and blocked the activation of these genes by 5-FU. Using chromatin immunoprecipitation assays, we provide experimental evidence to support the importance of the transcription factor Sp1 in the mechanism of p53-mediated upregulation of the p21
Cip1 gene by drugs such as 5-FU.
Results
Mithramycin A is a strong activator of the tumor suppressor p53 protein in human hepatoma HepG2 cells
In a search for drugs that could activate p53 in human hepatoma cells, we found that mithramycin A is a strong activator of endogenous p53 protein in HepG2 cells. Activation of p53 by mithramycin A was fast, starting at 1 h and reached a maximum at 30 h post drug addition ( Figure 1a) . A similar time course of p53 activation was observed using the nucleotide analog 5-FU, a widely used chemotherapeutic drug with well-characterized p53-activating functions (Longley et al., 2003) . In the case of 5-FU, p53 activation was associated with a delayed activation of the cell cycle inhibitor p21 Cip1 gene, which started between 12 and 24 h and peaked at 36 h post drug addition (Figure 1b ). In contrast, mithramycin A had no effect on the expression of the p21
Cip1 gene in HepG2 cells (Figure 1a ). The findings indicate that p53 activation during genotoxic stress is not sufficient for p21
Cip1 gene induction but additional factors are required for this response, which are apparently inhibited or not activated by mithramycin A.
To investigate potential phosphorylation of p53 by mithramycin A, HepG2 cells were treated with this drug or with 5-FU for 24 h and phosphorylation of p53 was monitored by immunoblotting using a panel of antibodies recognizing different site-specific phosphorylated forms of p53. As shown in Figure 1c , both 5-FU and mithramycin A induced the phosphorylation of endogenous p53 at Ser 15. In contrast, no phosphorylation could be observed using antibodies recognizing p53 phosphorylated at serine residues 6, 9, 20, 37, 46 and 392 (data not shown). The finding indicates that both 5-FU and mithramycin A possibly utilize a similar mechanism for p53 activation which involves its phosphorylation by common stress-inducible protein kinases. Cip1 , p53, p63 and a-tubulin as indicated by immunoblotting. For comparison, extracts from HepG2 cells pretreated with 5-FU for 24 h were also included in the blot. (c) HepG2 cells were treated with 50 mg/ml 5-FU, 200 ng/ml mithramycin A independently or in combination for 24 h or left untreated (À). Reverse transcription PCR was performed using primers specific for the p21 Cip1 and ARP-PO genes. The arrows show the positions of the corresponding PCR products. (d) COS-7 cells were transfected with an expression vector bearing a 6myc-tagged human p21
Cip1 cDNA under the control of the CMV promoter/enhancer. Cells were treated with 200 ng/ml mithramycin A for 24 h or left untreated. Whole cell extracts were analysed for the expression of exogenous 6myc-p21 protein by immunoblotting using the anti-myc (9E10) monoclonal antibody. (e) HepG2 cells were treated with 50 mg/ml 5-FU, 200 ng/ml mithramycin A independently or in combination for 18 or 24 h or left untreated (À). Extracts form the treated or untreated HepG2 cells were subjected to immunoblotting using antibodies for PUMA, BAK and a-tubulin as indicated Figure 2a , both 5-FU and mithramycin A activated the endogenous p53 protein to similar levels, whereas the addition of both drugs simultaneously did not cause any additional p53 activation in agreement with the data of Figure 1c regarding a common mechanism of p53 activation by the two drugs. Importantly, mithramycin A totally abolished p21
Cip1 gene induction by 5-FU (Figure 2a ). This inhibition was not due to a general defect in gene expression since mithramycin A treatment of HepG2 cells had no effect on the expression of the endogenous Sp1 or a-tubulin genes (Figure 2a) .
We next investigated the genotoxic effects of the two drugs in HaCaT keratinocytes, which express, at high levels, a mutant p53 protein and its homolog p63 (Lehman et al., 1993; Hall et al., 2000) . As shown in Figure 2b , no induction of p53, p63 or p21
Cip1 was observed in the presence of either 5-FU or mithramycin A. In a control experiment, treatment of HaCaT cells with 200 pM of Transforming Growth Factor b (TGFb) for 24 h resulted in a significant induction of the endogenous p21 Cip1 gene expression in these cells (Figure 2b ) . No change in the expression of a-tubulin gene by either drug was observed (Figure 2b ).
Using reverse transcription-Polymerase chain reaction (RT-PCR), we showed that the inhibitory effect of mithramycin A on p21
Cip1 gene induction was at the level of transcription. As shown in Figure 2c , mithramycin A did not affect basal p21
Cip1 gene transcription but totally blocked the transcriptional induction of this gene by 5-FU (compare lanes 2 and 4). Neither 5-FU nor mithramycin A had any effect on the basal mRNA levels of the acidic ribosomal phosphoprotein (ARP-PO) gene that was used as a control ( Figure 2c ). We confirmed that the inhibitory effect of mithramycin A on the expression of the endogenous p21
Cip1 gene is exerted primarily at the level of transcription by showing that mithramycin A had only a minor effect on p21 Cip1 expression driven by the heterologous cytomegalovirus (CMV) promoter/enhancer in COS-7 cells ( Figure 2d ). This experiment also showed that mithramycin A does not seem to have a destabilizing effect on the p21
Cip1 protein itself. The findings of Figure 2a -d suggested that mithramycin A is a potent inhibitor of p53-mediated p21 gene activation during genotoxic stress by blocking the inducible but not the basal p21
Cip1 gene transcription.
Mithramycin A blocks the activation of the proapoptotic genes PUMA and BAK (bcl2-homologous antagonist/ killer by 5-FU
In addition to causing cell cycle arrest by activating the transcription of the p21 Cip1 gene, chemotherapeutic agents such as 5-FU are also strong inducers of apoptosis, the latter property being mediated by a number of proapoptotic p53 target genes including the Bcl-2 family members BAX and BAK and the genes encoding for the mitochondrial proteins NOXA, P53AIP1 and PUMA (Vogelstein et al., 2000; Yu et al., 2003) . We investigated the effect of 5-FU and mithramycin A on the expression of two proapoptotic genes, PUMA and BAK in HepG2 cells. As shown in Figure Importance of the proximal Sp1-binding sites for the activation of the p21
Cip1 promoter by DNA-damaging agents
We have shown previously that the proximal region of the p21
Cip1 promoter contains multiple binding sites for members of the Sp1 family of transcription factors and is essential for the activation of this promoter in human hepatoma cells (Koutsodontis et al., 2001; . To investigate the potential contribution of the proximal GC-rich motifs of the p21
Cip1 promoter in the mechanism of p21
Cip1 gene induction by chemotherapeutic drugs, we generated stably transfected HepG2 cell lines bearing the luciferase reporter gene under the control of either the wild-type (wt) (À2325/ þ 8) p21
Cip1 promoter or a mutant p21
Cip1 promoter bearing an internal deletion between nucleotides À125/À60. This internal deletion removed five out of six Sp1/Sp3-binding motifs of this region (Figure 3a ) (Moustakas and Kardassis, 1998) . As shown in Figure 3b , 5-FU induced the activity of the wt (À2325/ þ 8) p21 promoter in a dosedependent manner. In contrast, 5-FU did not induce the activity of the mutant À2325/ þ 8 (D-125/-60) p21 promoter lacking the proximal Sp1/Sp3-binding sites (Figure 3c ). The data of Figure 3 established an essential role of the proximal p21
Cip1 promoter region, which contains multiple binding sites for Sp1 and the related Sp3 protein, for the p21 Cip1 gene induction in response to 5-FU.
To investigate further the mechanism of inhibition of p53 target genes by mithramycin A, we performed transactivation experiments in SL2 cells. SL2 cells lack Sp1 and related activities and thus they represent a useful system to study mechanisms of Sp1-mediated transcriptional responses (Schneider, 1972) . In these experiments, we used, in addition to the human (À2325/ þ 8) p21 promoter, the promoter of the human PUMA gene (nucleotides À336/ þ 157). This promoter, similarly to the promoter of the p21 Cip1 gene, contains two p53-binding sites placed in the vicinity of a cluster of putative Sp1/Sp3-binding sites in the proximal region ( Figure 4a ) (Yu et al., 2001) . As shown in Figure 4 , overexpression of Sp1 in SL2 cells strongly induced p21
Cip1 (panel b) and PUMA (panel c) promoter activity and this induction was totally abolished in the presence of mithramycin A. Overexpression of p53 alone in SL2 cells was not sufficient to induce the activity of the p21
Cip1 and PUMA promoters. In contrast, coexpression of p53 along with Sp1 in SL2 cells restored the p53 responsiveness of the two promoters and resulted in extremely high levels of synergistic transactivation of both promoters which was abolished by mithramycin A (Figure 4b and c) .
The findings of Figure 3 and 4 suggested that the inhibitory effect of mithramycin A on p21
Cip1 and PUMA gene transcription could be due to the interference of this drug with the binding of transcription factor Sp1 and related proteins to the promoters of these genes. Indeed, mithramycin A inhibited the binding of Sp1 and Sp3 proteins to a previously characterized oligonucleotide probe corresponding to Sp1 site 3 of the proximal p21
Cip1 promoter (Figure 5b lanes 1 and 2) (Koutsodontis et al., 2002) . In contrast, mithramycin A did not affect the binding of p53 to its cognate-binding site on the distal p21
Cip1 promoter region (Figure 5b lanes 3 and 4).
Both 5-FU and mithramycin A enhance the recruitment of p53 to the p21 Cip1 promoter in vivo
We then proceeded to characterize the recruitment of p53 and Sp1 transcription factors to the p21 Cip1 gene promoter in HepG2 cells under conditions of genotoxic stress using the chromatin immunoprecipitation (ChIP) assay (Kuo and Allis, 1999; Orlando, 2000) . Four different sets of primers were utilized in these assays corresponding to the proximal, middle and distal p21 Cip1 promoter regions as well as to a control region located approximately 1000 bp upstream of the distal p53-binding site (Figure 5a ). The proximal primers were used to monitor the recruitment of Sp1, whereas the middle and distal primers were used to monitor the recruitment of p53 to its cognate sites on the p21 Cip1 promoter. The control primers were used to exclude the possibility of immunoprecipitation of unrelated chromatin.
As shown in Figure 5c (upper panel, lane 2), a low, basal level of p53 recruitment to the distal p21 Using the ChlP assay, we also established that Sp1 is not constitutively recruited to the proximal p21 Cip1 promoter was observed (Figure 5d ). In summary, using the ChlP assay, we were able to provide a mechanistic explanation for the observed activation of p21
Cip1 gene transcription by 5-FU as well as for the inhibitory role of mithramycin A on p21 Cip1 gene induction by 5-FU.
Mithramycin A does not affect the physical interactions between p53 and Sp1
Next, we employed a novel protein-protein interaction assay that is based on protein biotinylation in vivo (de Boer et al., 2003) in order to demonstrate drug-inducible physical interactions between Sp1 and p53 in HepG2 cells. For this purpose, a plasmid vector was constructed bearing the human Sp1 cDNA (coding for amino acids 83-778) fused, at its N-terminus, with a short 23 aminoacid peptide that is a target for the bacterial protein ligase BirA (Figure 6a The findings of Figure 6b were confirmed using glutathione S transferase (GST) pull down assays in vitro. For this purpose, bacterially expressed and purified GST or GST-Sp1 (aa 83-778) were coupled to glutathione-Sepharose beads (Figure 6c ) and allowed to interact with extracts from HepG2 cells pretreated with either 5-FU or mithramycin A for 24 h in order to induce the expression of endogenous p53 protein. As shown in Figure 6d , efficient interaction between GSTSp1 and endogenous p53 protein was observed under both conditions suggesting that mithramycin A has no effect on the affinity of p53 for Sp1.
In summary, the data of Figure 6 suggest that genotoxic agents that activate p53, such as 5-FU and mithramycin A, induce the formation of p53/Sp1 complexes in solution.
Discussion
In the present study we showed that mithramycin A, an aureolic acid-type polyketide produced by the soil bacteria S. argillaceus (Jayasuriya et al., 2002) , which has been utilized clinically in the US to treat Paget's disease and testicular carcinoma (Brown and Kennedy, 1965; Ryan et al, 1970; Elias and Evans, 1972; , has a dual effect on cells. On the one hand, it strongly activates the p53 tumor suppressor protein by inducing its phosphorylation at Ser 15. On the other hand, due to its ability to inhibit the binding of Sp1 transcription factor to GC-rich motifs, mithramycin A inhibits the activation of a specific subset of p53 target genes that are also regulated by Sp1 such as the p21 Cip1 , the PUMA, and the BAK genes.
Our ChlP experiments provided important information regarding the recruitment of p53 and Sp1 transcription factors to the p21 Cip1 promoter in vivo during genotoxic stress induced by the drugs 5-FU and mithramycin A. Our results established that Sp1 and possibly factors related to Sp1 such as Sp3 are not constitutively recruited to the proximal p21
Cip1 promoter in HepG2 cells under basal conditions. Sp1 recruitment to this region is substantially enhanced following the addition of the drug 5-FU but not of mithramycin A (Figure 5c ). Mechanistically, this result could be explained by a putative post-translational modification of Sp1 such as phosphorylation or acetylation, catalysed by 5-FU-inducible enzymes, which could enhance the affinity of Sp1 for DNA. In support of this hypothesis, it has been shown recently that a novel class of antitumor agents, the alkylphospholipids, induce p21
Cip1 gene Alternatively, 5-FU could enhance or stabilize the formation of p53/Sp1 complexes in solution via proteinprotein interactions. Thus, 5-FU could enhance the recruitment of preformed p53/Sp1 complexes to the proximal and distal p21
Cip1 promoter regions simultaneously. In support of this model, we demonstrated here, by employing a novel protein-protein interaction assay based on protein biotinylation in vivo, 5-FUinducible physical interactions between Sp1 and p53 in HepG2 cells (Figure 6 ). Interactions between p53 and Sp1 or Sp3 factors in solution have also been reported previously (Koutsodontis et al., 2001; SchavinskyKhrapunsky et al., 2003) . Mithramycin A also induced the formation of p53/Sp1 complexes in solution (Figure 6 ), but these complexes were not recruited to the p21
Cip1 promoter due to the inhibitory effect of mithramycin A on Sp1 DNA binding.
The experiments of this study showed that mithramycin A affects the inducible and not the constitutive transcription of the human p21
Cip1 gene in HepG2 cells (Figure 2c ). This is in agreement with the results from the ChIP experiment of Figure 5c which showed that Sp1 is bound to the p21 Cip1 promoter only during stimulation by the drug 5-FU. These findings suggest that Sp1 as well as related factors (Sp3) are not crucial for the low, basal level of expression of the p21 Cip1 gene but are essential for the inducible p21
Cip1 gene expression by interacting physically and functionally with other transcription factors such as p53. These interactions could be required for the stabilization of the protein complexes that need to bind simultaneoulsy to separate promoter regions, such as the proximal and the distal regions of the p21
Cip1 promoter, in order to activate transcription.
We showed that 5-FU and mithramycin A are effective p53 activators in one cellular context (human hepatoma HepG2 cells) but not in another (human HaCaT keratinocytes). The critical difference between these two cell lines is that HepG2 cells express a normal p53 protein and no other p53 family members (Koutsodontis and Kardassis, unpublished observations), whereas HaCaT keratinocytes express a mutant p53 bearing the double inactivating mutation in the DNAbinding domain (mutation Y179/W282) (Lehman et al., 1993) . Thus, p53 in HaCaT cells cannot be further stabilized by 5-FU or mithramycin A and cannot bind to DNA due to the mutations. The inability of the endogenous p63 protein to substitute for the mutant p53 in p21
Cip1 gene induction by 5-FU in HaCaT is intriguing. It is possible that the double mutation in the endogenous p53 in HaCaT cells confers a dominant negative phenotype over the p63 function, a hypothesis that is experimentally supported by a recent study (Strano et al., 2002) . The same study demonstrated that in cells carrying endogenous mutant p53, p63 is unable to be recruited to its target gene promoters (Strano et al., 2002) . In support of these observations, we were unable to demonstrate, using ChIP assays, the recruitment of p53 or p63 proteins to the p21 promoter in HaCaT cells either untreated or treated with 5-FU or mithramycin A (Koutsodontis and Kardassis, unpublished observations). The 23 amino-acid peptide that was fused to the Sp1 protein to facilitate its biotinylation is also shown. The asterisk indicates the lysine residue that is biotinylated by BirA in vivo. (b) HepG2 cells were transfected in 10-cm dishes with 7.5 mg of the pCDNA3-Bio-Sp1 expression vector in the presence or absence of 7.5 mg of pCDNA3-BirA vector. 5-FU (50 mg/ml) or mithramycin A (200 ng/ml) was added to the culture 16 h post-transfection. After 24 h, cells were lysed and cell extracts were allowed to interact with Streptavidin agarose beads. Bound proteins as well as a fraction of the starting material (WCE) were subjected to SDS-PAGE (Polyacrylamide-gel electrophoresis) followed by immunoblotting using anti-p53 or streptavidin-HRP and visualized by enhanced chemiluminescence. (c, d) GST or GST-Sp1 fusion proteins were expressed in Escherichia coli, purified and coupled to glutathione-Sepharose beads. The coupling efficiency was monitored by SDS-PAGE and Coomassie brilliand blue staining (panel c). The asterisks show the position of the GST and GST-Sp1 (83-778) proteins. GST and GST-Sp1 (83-778) beads were allowed to interact with extracts from HepG2 cells treated with 5-FU (50 mg/m) or mithramycin (200 ng/ml) for 24 h to activate the endogenous p53 protein.
Binding of p53 to the beads was monitored by SDS-PAGE and Western blotting using the anti-p53 monoclonal antibody DO-1 (panel d). The arrow shows the position of the p53 Also, we could not detect any binding of Sp1 to the proximal p21 promoter in vivo (data not shown) despite the high levels of endogenous p53 and p63 in HaCaT cells which is in agreement with the data in HepG2 cells in which no binding of Sp1 was observed in the absence of p53 activation (Figure 5c ).
According to our current model, which is shown schematically in Figure 7 , the mechanism of transcriptional induction of the p21
Cip1 gene by genotoxic agents such as 5-FU involves the following steps: activation of endogenous p53 via phosphorylation at Ser 15, recruitment of activated p53 to the distal and middle p21 Cip1 promoter-binding sites, enhanced recruitment of Sp1 or related factors to the proximal p21
Cip1 promoter and synergistic interactions between p53 and Sp1 bound to the p21
Cip1 promoter which leads to transcriptional activation. An alternative model could be proposed taking into account potential drug-inducible formation of p53/Sp1 complexes in solution (i.e. prior to DNAbinding) and the subsequent simultaneous recruitment of the two factors to the p21
Cip1 promoter. Although we do not have sufficient experimental evidence to support the one versus the other model, we do have evidence for physical interactions between p53 and Sp1 in solution in the absence of DNA binding (Figure 6 ).
In the case of mithramycin A (Figure 7b ), this drug, in addition to the activation of p53, has a genotoxic effect on GC-rich regions in chromatin, including the one present on the proximal p21
Cip1 promoter. Recruitment of p53 to the distal and middle p21
Cip1 promoter regions takes place normally; however, no Sp1 (and possibly of the related Sp3) binding to the proximal p21 Cip1 promoter occurs due to the presence of mithramycin A. Physical interactions between Sp1 and p53 in solution are not affected by mithramycin A ( Figure 6) ; however, step 4, that is functional synergism between p53 and Sp1 on the p21
Cip1 promoter, is disturbed due to the absence of Sp1/Sp3 factors on the p21
Cip1 promoter. The net result of mithramycin A treatment is inhibition of inducible p21
Cip1 gene transcription. Understanding in depth the mechanism of action of drugs such as 5-FU and mithramycin A and identifying putative target genes that could be transcriptionally activated or repressed by these drugs will be essential for the proper utilization of these drugs in disease therapy which requires lower toxicity and the highest clinical benefit.
Materials and methods

Materials
All reagents for cell culture were purchased from Invitrogen/ Life Technologies (Carlsbad, CA, USA). Mithramycin A, 5-FU, Protein G Sepharose, Streptavidin agarose and the antimyc (9E10) monoclonal antibody were purchased from SigmaAldrich (St Louis, MI, USA). The anti-p53, anti-Sp1 and antip63 mouse monoclonal antibodies were purchased from Santa Cruz Biotech (Santa Cruz, CA, USA). The phospho-p53 antibody sampler kit was purchased from Cell Signaling Technology (Beverly, MA, USA). The anti-p21 mouse monoclonal antibody was purchased from Transduction Labs. TGFb1 was purchased from R&D Systems Inc. (Minneapolis, MN, USA). The anti-a-tubulin monoclonal antibody was a gift of Dr C Stournaras (University of Crete, Heraklion, Greece). The anti-Bak monoclonal antibody was a gift of Dr A Gravanis (University of Crete, Heraklion, Greece). The anti-PUMA antibody was a generous gift of Dr J Yu (University of Pittsburgh, Pittsburg, PA, USA). Glutathione-sepharose 4B was purchased from Amersham-Pmarmacia. Anti-mouse and anti-rabbit peroxidase conjugated secondary antibodies were purchased from Chemicon International Inc. (Temecula, CA, USA).
Plasmids
The À2325/ þ 8 p21-luc and the À2325/ þ 8 (DÀ125/À60) p21-luc promoter plasmids has been described previously (Moustakas and Kardassis, 1998) . The À336/ þ 157 PUMA-luciferase reporter plasmid was a generous gift of Dr Bert Vogelstein (Johns Hopkins University, MD, USA). The pGEX and pGEX-Sp1 (81-778) bacterial expression vectors have been described previously . Plasmid pCDNA1amp/6myc-p21 was constructed by cloning of a PCR-amplified fragment corresponding to the human p21 Cip1 cDNA into the pCDNA1amp/6myc vector (Kardassis et al., Cip1 cDNA were 5 0 -GGG GAA TTC TCA GAA CCG GCT GGG GAT GTC CGT CAG-3 0 (sense); 5 0 -TCA AGC TTC TTA GGG CTT CCT CTT GGA GAA GAT CAG-3 0 (antisense). The expression vector pCDNA3-Bio-Sp1, used for the in vivo biotinylation of Sp1, was constructed by subcloning the human Sp1 cDNA (coding for amino-acid residues 83-778) into the expression vector pCDNA3-Bio in frame with a 23 amino-acid peptide which is a target for the biotin protein ligase BirA (de Boer et al., 2003) . The cDNA for bacterial BirA was a kind gift of Dr John Strouboulis (Erasmus University, The Netherlands).
Cell cultures and transfections
Human hepatoma HepG2 cells, COS-7 fibroblasts and HaCaT keratinocytes were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), L-glutamine and penicillin/streptomycin at 371C, in a 5% CO 2 atmosphere. Drosophila embryo Schneider's SL2 cells were cultured in Schneider's insect medium supplemented with 10% insect culture-tested FBS and penicillin/streptomycin at 251C. Transient transfections were performed by the Ca 3 (PO 4 ) 2 co-precipitation method. For the generation of stably transfected cell clones, HepG2 cells (5 Â 10 5 cells/60 mm plate) were transfected with 7.5 mg of reporter plasmid and 7.5 mg of a plasmid encoding the neomycin-resistance gene (pCDNA1-neo). The following day, cells were trypsinized, transferred to 100-mm plates in serial dilutions and grown in DMEM (10% FBS) supplemented with 1 mg/ml neomycin. Cell clones were picked and cultured in the presence of 1 mg/ml neomycin.
ChlPs
The ChlP assay was performed as described previously (Hatzis and Talianidis, 2001 ) using antibodies for p53 and Sp1 proteins. Immunoprecipitated chromatin was analysed by PCR using primers corresponding to different regions of the human p21
Cip1 promoter. Proximal p21 Cip1 promoter primers: 5 0 -TGT GTC CTC CTG GAG AGT GC-3 0 and 5 0 -AGC TTG CTG AGC CTG GCC GAG TTC CAG CA-3 0 . Middle p21 
Gel electrophoretic mobility shift assays
Gel electrophoresic mobility shift assays were performed as described previously Ladias et al., 1992) . The sequence of the sense oligonucleotides used as probes is as follows:
Sp1: 5 0 -GGG GGT CCC GCC TCC TTG A-3 0 . p53: 5 0 -GGG ATC AGG AAC ATG TCC CAA CAT GTT GAG CTC T-3 0 .
RT-PCR analysis
HepG2 cells were treated with 50 mg/ml 5-FU or 200 ng/ml mithramycin for 24 h or left untreated, total RNAs were prepared and treated with 10 U of DNase I for 30 min at room temperature. The RNA was extracted with phenol-chloroform and precipitated with ethanol. cDNA synthesis was performed with SuperScript reverse transcriptase using random hexamers as primers. The cDNAs were directly used for PCR amplification with primers corresponding to the human p21 Cip1 cDNA. The sequences of the primers were: sense 5 0 -CTG CCC AAG CTC TAC CTT CC-3 0 , antisense 5 0 -CAG GTC CAC ATG GTC TTC CT-3 0 . For normalization, the human acidic ribosomal phosphoprotein (ARP-PO) was amplified as described (Hatzis and Talianidis, 2001) . PCR products were analysed by agarose gel electrophoresis.
GST pull down assays
The GST fusion proteins were expressed in E. coli strains BL21 or DH-5a using standard protocols. Glutathione-Shepharose 4B beads were equilibrated in PBS and mixed with one volume of bacterially expressed GST fusion proteins on a rotary shaker O/N at 41C. The beads were washed three times with 10 volumes of PBS containing 1% Triton X-100. Coupling efficiency was monitored by SDS-PAGE and Coomassie blue staining. GST pull down assays were performed as described previously (Koutsodontis et al., 2001 ).
In vivo biotinylation and protein-protein interaction assay
For the in vivo biotinylation assay (de Boer et al., 2003) , HepG2 cells were transfected in 10-cm dishes with 7.5 mg of the pCDNA3-Bio-Sp1 expression vector in the presence or in the absence of 7.5 mg of pCDNA3-BirA vector expressing the bacterial biotin ligase BirA. 5-FU (50 mg/ml) or mithramycin A (200 ng/ml) was added to the culture 16 h post-transfection. At 48 h post-transfection, cells were lysed in lysis buffer (20 mM Tris-HCl pH ¼ 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100) and allowed to interact with Streptavidin agarose beads for 3 h at 41C in a rotating platform. Beads were washed three times with lysis buffer and centrifuged at 4000 r.p.m. for 1 min at room temperature. Bound proteins as well as the starting material (input) were subjected to SDS-PAGE followed by immunoblotting using anti-p53 or streptavidin-HRP (horseradish peroxidase) and visualized by enhanced chemiluminescence on X-Ray film as described above.
Abbreviations 5-FU, 5-fluorouracil; ARP-PO, acidic ribosomal phosphoprotein; BAK, bcl2-homologous antagonist/killer; BSA, bovine serum albumin; ChIP, chromatin immunoprecipitation; CMV, cytomegalovirus; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; GST, glutathione S transferase; NP-40, Nonidet P-40; PAGE, polyacrylamide gel electrophoresis; HRP, horseradish peroxidase; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; PUMA, p53-upregulated mediator of apoptosis; WB, Western Blotting; wt, wild type; WCE, whole cell extracts.
